CYSLTR1 and colonic neoplasm: A previous study indicated that MMP9 activity and expression were reduced by a CYSLTR1 antagonist (montelukast), and that M2 macrophages enriched in leukotriene D4 promoted the migration and invasion of colon cancer cells by inducing MMP9 expression [33].